Clinical Trial Update: Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD alone for platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Recurrent Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | Status: UNKNOWN